These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 28652654)

  • 41. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
    Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation.
    Chanvorachote P; Pongrakhananon V; Wannachaiyasit S; Luanpitpong S; Rojanasakul Y; Nimmannit U
    Cancer Invest; 2009 Jul; 27(6):624-35. PubMed ID: 19283527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.
    Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4883-4894. PubMed ID: 38165424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.
    Ke F; Wang Z; Song X; Ma Q; Hu Y; Jiang L; Zhang Y; Liu Y; Zhang Y; Gong W
    Drug Des Devel Ther; 2017; 11():1753-1766. PubMed ID: 28670110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.
    Weiß LM; Hugle M; Romero S; Fulda S
    Int J Cancer; 2016 Jan; 138(2):497-506. PubMed ID: 26260582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis.
    Kim JH; Liu L; Lee SO; Kim YT; You KR; Kim DG
    Cancer Res; 2005 Jul; 65(14):6312-20. PubMed ID: 16024633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
    Sahin K; Tuzcu M; Yabas M; Orhan C; Sahin N; Ozercan IH
    Invest New Drugs; 2018 Jun; 36(3):388-395. PubMed ID: 29139009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
    Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
    Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.
    Wu M; Wang Y; Yang D; Gong Y; Rao F; Liu R; Danna Y; Li J; Fan J; Chen J; Zhang W; Zhan Q
    EBioMedicine; 2019 Mar; 41():244-255. PubMed ID: 30876762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
    Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
    J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
    De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
    Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mycoepoxydiene induces apoptosis and inhibits TPA-induced invasion in human cholangiocarcinoma cells via blocking NF-κB pathway.
    Li W; Li M; Su X; Qin L; Miao M; Yu C; Shen Y; Luo Q; Chen Q
    Biochimie; 2014 Jun; 101():183-91. PubMed ID: 24486723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
    Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
    Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
    Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
    Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
    Ergul M; Bakar-Ates F
    Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells.
    Zhang Z; Zhang G; Kong C
    J Cell Mol Med; 2017 Apr; 21(4):758-767. PubMed ID: 27878946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.